Advanced SearchSearch Tips
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Biomolecules & Therapeutics
  • Volume 23, Issue 6,  2015, pp.493-509
  • Publisher : The Korean Society of Applied Pharmacology
  • DOI : 10.4062/biomolther.2015.116
 Title & Authors
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Kim, Eunhee G.; Kim, Kristine M.;
  PDF(new window)
Antibody-drug conjugates utilize the antibody as a delivery vehicle for highly potent cytotoxic molecules with specificity for tumor-associated antigens for cancer therapy. Critical parameters that govern successful antibody-drug conjugate development for clinical use include the selection of the tumor target antigen, the antibody against the target, the cytotoxic molecule, the linker bridging the cytotoxic molecule and the antibody, and the conjugation chemistry used for the attachment of the cytotoxic molecule to the antibody. Advancements in these core antibody-drug conjugate technology are reflected by recent approval of Adectris(anti-CD30-drug conjugate) and Kadcyla(anti-HER2 drug conjugate). The potential approval of an anti-CD22 conjugate and promising new clinical data for anti-CD19 and anti-CD33 conjugates are additional advancements. Enrichment of antibody-drug conjugates with newly developed potent cytotoxic molecules and linkers are also in the pipeline for various tumor targets. However, the complexity of antibody-drug conjugate components, conjugation methods, and off-target toxicities still pose challenges for the strategic design of antibody-drug conjugates to achieve their fullest therapeutic potential. This review will discuss the emergence of clinical antibody-drug conjugates, current trends in optimization strategies, and recent study results for antibody-drug conjugates that have incorporated the latest optimization strategies. Future challenges and perspectives toward making antibody-drug conjugates more amendable for broader disease indications are also discussed.
Antibodies;Antibody-drug conjugates;Immunotherapy;Targeted therapy;
 Cited by
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates, Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 6, 567  crossref(new windwow)
Antibody–drug conjugates for targeted anticancer drug delivery, Journal of Pharmaceutical Investigation, 2016, 46, 4, 341  crossref(new windwow)
Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates, Bioconjugate Chemistry, 2016, 27, 4, 1030  crossref(new windwow)
Linkers Having a Crucial Role in Antibody–Drug Conjugates, International Journal of Molecular Sciences, 2016, 17, 4, 561  crossref(new windwow)
Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment, Interface Focus, 2016, 6, 6, 20160054  crossref(new windwow)
Recent progress in protein-protein interaction study for EGFR-targeted therapeutics, Expert Review of Proteomics, 2016, 13, 9, 817  crossref(new windwow)
Antibody drug conjugates, Biotechnology Letters, 2016, 38, 10, 1655  crossref(new windwow)
Determination of Antibody–Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation, Bioconjugate Chemistry, 2016, 27, 7, 1645  crossref(new windwow)
Bioconjugation – using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers, Org. Biomol. Chem., 2016, 14, 34, 8002  crossref(new windwow)